Seagen Inc.

Taiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c

The past year yielded a downward trend across the board for dealmaking in the biopharmaceutical sector, regardless of which metric one looks at. In the area of mergers and acquisitions, deal volume, t

Developing antibody therapeutics, out-licensing the drugs to larger companies and collecting royalty revenue from the resulting commercial products has been a lucrative business for Genmab. However, f

It was Groundhog Day on 2 February. That week, any pharmaceutical groundhogs would have emerged from their burrows, glanced at the shadows of tariffs, a global trade war and weak Chinese demand and sc